Merdury Biopharmaceutical

Merdury Biopharmaceutical EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Merdury Biopharmaceutical (6932.TWO) as of Oct 20, 2026 is -60.01. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -76.22 — a change of -21.26% (higher).

EV/FCF

-60.01

YoY

-21.26%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Merdury Biopharmaceutical is 2025 -60.01 . EV/FCF (Enterprise Value to Free Cash Flow) of Merdury Biopharmaceutical was 2024 -76.22 . It decreases by -21.26% higher compared to the previous year.

The Merdury Biopharmaceutical EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-17,518.00 TWD
Jan 1, 2020
-15,904.44 TWD
Jan 1, 2021
-280.67 TWD
Jan 1, 2022
-35.49 TWD
Jan 1, 2023
-56.79 TWD
Jan 1, 2024
-76.22 TWD
Jan 1, 2025
-60.01 TWD
The Merdury Biopharmaceutical EV/FCF history
YEAREV/FCFYoY
-60.01-21.26%
-76.22+34.20%
-56.79+60.02%
-35.49-87.35%
-280.67-98.24%
-15,904.44-9.21%
-17,518.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp develops and manufactures pharmaceutical products including Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, and multi-ingredient antihypertensive drugs. The company utilizes its StackDose platform to create controllable time-dissolving tablets for instant or sustained drug release. Products are primarily sold in Taiwan and the United States, targeting markets for drugs that do not meet special medical needs, difficult generics, and second-class new drugs. The company's revenue comes from the sale of these pharmaceutical products to customers in both regions. The firm's StackDose technology enables the development of specialized drug formulations that control the timing of drug effectiveness, differentiating its product range. This focus on innovative delivery systems supports sales in the pharmaceutical markets of Taiwan and the U.S., where demand exists for advanced generic and specialty medications. The company's product portfolio aligns with its strategic focus on non-special medical need drugs and second-class new drugs. Merdury Biopharmaceutical Corp targets healthcare providers and pharmacies in Taiwan and the United States as its primary customers. The company's self-developed StackDose platform allows for the creation of unique drug delivery systems that are sold under the company's own product lines. Sales of Sildenafil, Metformin, Tadalafil, and other key products form the core of the company's revenue streams. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

EV/FCF (Enterprise Value to Free Cash Flow) of Merdury Biopharmaceutical is -60.01 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Merdury Biopharmaceutical changed from -76.22 to -60.01, representing a -21.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical